Allogene Therapeutics, Inc.
ALLO
Key stats
- Open
- 0.89
- Day high
- 0.90
- Day low
- 0.82
- Previous close
- 0.90
- Volume
- 10.69M
- VWAP
- 0.86
- 52-week high
- 4.46
- 52-week low
- 0.82
- Market cap
- 311.86M
- Shares out
- 345.49M
- Employees
- 152
- Listed
- 2018
About Allogene Therapeutics, Inc.
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · SOUTH SAN FRANCISCO, CA · allogene.com
Options · expiring Nov 20
Nov 12, 3:59 PM ET- Call open interest
- 7.0K
- Put open interest
- 484
- Put/call
- 0.07
- At-the-money IV
- 344.6%
| Contract | Last | Traded | Volume | Open int. | IV |
|---|---|---|---|---|---|
| 1 put | 0.15 | Nov 12, 9:30 AM | 100 | 20 | — |
| 2 call | 0.03 | Nov 12, 3:48 PM | 52 | 3.1K | 545.1% |
| 1 call | 0.05 | Nov 10, 3:15 PM | 30 | 2.2K | 344.6% |
| 1.50 call | 0.05 | Nov 9, 9:36 AM | 20 | 788 | 1401.1% |
| 1.50 put | 0.65 | Nov 12, 2:29 PM | 10 | 241 | 338.0% |
| 0.50 call | 0.40 | Nov 12, 10:54 AM | 8 | 946 | — |
Quarterly results
Massive · Aug 12, 2026| Q2 2026 to Jun 30, 2026 | Q1 2026 to Mar 31, 2026 | Q4 2025 to Dec 31, 2025 | Q3 2025 to Sep 30, 2025 | |
|---|---|---|---|---|
| Revenue | $4.64M | $0 | $0 | $0 |
| Gross profit | $4.64M | $0 | $0 | $0 |
| Operating income | −$46.92M | −$46.09M | −$42.40M | −$44.90M |
| Net income | −$42.68M | −$42.61M | −$38.81M | −$41.40M |
| Diluted EPS | -0.13 | -0.18 | -0.17 | -0.19 |
| Operating cash flow | −$32.00M | −$12.91M | −$27.60M | −$29.69M |
| Assets | $550.09M | $395.96M | $415.90M | $439.77M |
| Liabilities | $113.92M | $117.08M | $123.36M | $124.44M |
| Equity | $436.18M | $278.88M | $292.54M | $315.33M |
Technicals
Massive · Nov 12, 2026- 50-day average1.43
- 200-day average1.95
- RSI (14 days)22.1
Short interest
Massive · Oct 30, 2026- Oct 30, 202651.29M shares · 6.2 days to cover
- Oct 15, 202653.41M shares · 9.3 days to cover
- Sep 30, 202655.61M shares · 9.0 days to cover
- Sep 15, 202659.60M shares · 11.3 days to cover
News coverage
No stories about Allogene Therapeutics, Inc. right now.